Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa.

Autor: Budgell EP; Health Economics and Epidemiology Research Office (HE2RO), Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; †Right to Care, Johannesburg, South Africa; ‡Center for Global Health & Development, Boston University, Boston, MA; and §Department of Epidemiology, Boston University School of Public Health, Boston University, Boston, MA., Maskew M, Long L, Sanne I, Fox MP
Jazyk: angličtina
Zdroj: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2015 Nov 01; Vol. 70 (3), pp. 323-8.
DOI: 10.1097/QAI.0000000000000755
Abstrakt: In resource-limited settings, early mortality on antiretroviral therapy (ART) is approximately 10%; yet, it is unclear how much of that mortality occurs in care or after lost to follow-up. We assessed mortality rates and predictors of death among 12,222 nonpregnant ART-naive adults initiating first-line ART between April 2004 and May 2012 in South Africa, stratified by person-years in care and lost. We found 14.6% of patients died and being lost accounted for a minority of deaths across multiple definitions of loss (population attributable-risk percent ranged from 10.4% to 42.5%). Although mortality rates in patients lost were much higher than in care, most ART-related mortality occurred on treatment.
Databáze: MEDLINE